EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice.
Scid mice develop human EBV-positive B cell tumors after injection with EBV-transformed human B cells or peripheral blood lymphocytes from EBV-seropositive donors. Injection of cytotoxic T cell (CTL) lines, selectively expanded in vitro to recognize autologous EBV-transformed B cells, protected mice against developing human lymphoproliferative disease. CTL protection required a single dose of polyethylene-glycol-conjugated IL2. Mice were not protected by CTL that did not specifically recognize EBV-transformed B cells or by mitogen-activated lymphocytes.
Buchsbaum
R J
RJ
Department of Medicine, New England Medical Center, Boston, MA, USA.
Fabry
J A
JA
Lieberman
J
J
D019264:Adoptive Transfer; D000818:Animals; D002460:Cell Line; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000472:pathogenicity*; D006801:Humans; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014183:Transplantation, Heterologous